H.A. Zhylitskaya et al. / Steroids 77 (2012) 1169–1175
1171
(
(
49), 2118 (24), 1802 (12), 1680 (33), 1624 (52), 1652 (100), 1207
42), 1222 (14), 1180 (32).
2.2.9. Conjugate of 5,10,15,20-tetrakis(4-dihydroxylborylphenyl)por-
phyrin with 24-epibrassinolide (13)
Product 13 (38 mg, 78%) was obtained as a purple solid from
porphyrin 9 (15 mg, 0.019 mmol) and EBl (prepared according to
[
36], 40 mg, 0.083 mmol). m.p. (MeOH): >350 °C. UV kmax, nm (e,
1
Fig. 1. Chemical structures of 20-hydroxyecdysone (20E) and 24-epibrassinolide
L/(cmÁmol)): [DMA] 420 (312000), [DMSO] 420 (465000).
H
(
EBl).
NMR (500 MHz, C
5
D
5
N) d: À2.32 (s, 2H, NH), 0.74 (s, 12H,
C18–H), 0.91 (d, J = 6 Hz, 12H, C–21H), 1.10 (m, 36H, C19–H, C26/
C27–H), 1.20 (d, J = 5 Hz, 12H, C24–H), 3.67 (dd, J = 11, 4 Hz, 4H,
C5–H), 4.01–4.24 (m, 12H, C2–H, C7–H), 4.33 (m, 4H, C23–H),
pyrrole-H), 9.62 (d, J = 5 Hz, 4H, pyrrole-H), 10.61 (s, 2H, meso-H).
13
5 5
C NMR (125 MHz, C D N) d: 9.59, 11.59, 11.97, 15.78, 16.87
4
.45 (br.s, 4H, C3–H), 4.68 (d, J = 3 Hz, 4H, C22–H), 8.55 (d,
2
4
6
1
1.06, 22.44, 24.86, 27.72, 28.12, 29.83, 33.00, 38.45, 39.63,
1.62, 41.68, 42.56, 42.67, 44.86, 51.22, 52.76, 58.30, 68.31,
8.60, 70.14, 83.17, 83.83, 106.06, 119.30, 131.27, 132.46, 133.98,
J = 6 Hz, 8H, Ph-H), 8.61 (d, J = 6 Hz, 8H, Ph-H), 9.14 (s, 8H, pyr-
role-H). C NMR (125 MHz, C
1
4
7
1
3
5
D
5
N) d: 9.48, 11.54, 11.91, 15.78,
6.69, 21.04, 22.39, 24.81, 27.59, 28.07, 32.99, 38.42, 39.57,
34.81, 144.54, 145.71, 147.27, 158.42, 176.49. MS MALDI-TOF
1.59, 42.49, 42.63, 44.84, 51.17, 52.68, 58.25, 68.31, 68.60,
0.10, 83.07, 83.89, 120.71, 133.80, 134.63, 145.28, 176.51. MS
+
m/z (rel. int.%): 1440 [M+H] (41), 1001 (30), 967 (100). HR ESIMS
m/z: 1439.8561 [M+H] (calcd for C88H B N O12+H, 1439.8541).
112 2 4
+
+
+
MALDI-TOF m/z (rel. int.%): 2591 [M+Na] (3), 2569 [M+H] (53),
097 (100), 1624 (35).
2
2.2.12. Conjugate of 5,15-bis[4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)phenyl]-10,20-bispentafluorophenylporphyrin with
2
.2.10. Conjugate of 5,15-bis(4-dioxylborylphenyl)porphyrin with 20-
20-hydroxyecdysone (16)
hydroxyecdysone (14)
Product 14 (35 mg, 93%) was obtained as a purple solid from
porphyrin 10 (14 mg, 0.025 mmol) and 20E (27 mg, 0.055 mmol).
Conjugate 16 (30 mg, 85%) was prepared as purple solid from
porphyrin 11 (17 mg, 0.020 mmol) and 20E (21 mg, 0.044 mmol).
m.p. (MeOH): >350 °C. UV kmax, nm ( , L/(cmÁmol)): 417 (255000)
DMA], 418 (263000) [DMSO]. H NMR (500 MHz, C N) d:
À2.54 (s, 2H, NH), 1.16 (s, 6H, C18–H), 1.27 (s, 6H, C19–H), 1.55
d, J = 4 Hz, 12H, C26/C27–H), 1.71 (s, 6H, C21–H), 3.01 (t,
J = 8 Hz, 2H, C17–H), 3.09 (dd, J = 13, 3 Hz, 2H, C5–H), 3.66 (m,
e
1
m.p. (MeOH): >350 °C. UV kmax, nm (
e
, (L/cmÁmol)): [DMA] 407
335000), [DMSO] 409 (323000). H NMR (500 MHz, C N) d:
À2.65 (s, 2H, NH), 1.17 (s, 6H, C18–H), 1.31 (s, 6H, C19–H), 1.57
d, J = 4 Hz, 12H, C26/C27–H), 1.73 (s, 6H, C–21H), 3.03 (t,
J = 8 Hz, 2H, C17–H), 3.11 (dd, J = 13, 2 Hz, 2H, C5–H), 3.68 (m,
[
5 5
D
1
(
5 5
D
(
(
2
4
H, C9–H), 4.25 (br d, J = 12 Hz, 2H, C2–H), 4.31 (br s, 2H, C3–H),
.65 (d, J = 11 Hz, 2H, C22–H), 6.34 (s, 2H, C7–H), 6.59 (s, 2H,
2
4
H, C9–H), 4.26 (br d, J = 11 Hz, 2H, C2–H), 4.32 (br s, 2H, C3–H),
.67 (d, J = 11 Hz, 2H, C22–H), 6.37 (s, 2H, C7–H), 6.62 (s, 2H,
OH), 8.54 (d J = 8 Hz, 4H, Ph-H), 8.59 (d, J = 8 Hz, 4H, Ph-H), 9.31
d, J = 4 Hz, 4H, pyrrole-H), 9.49 (d, J = 4 Hz, 4H, pyrrole-H). 13
N) d: 18.69, 22.42, 23.56, 24.37, 25.82,
C
OH), 8.47 (d, J = 8 Hz, 4H, pyrrole-H), 8.60 (d, J = 8 Hz, 4H, pyr-
role-H), 9.25 (d, J = 4 Hz, 4H, Ph-H), 9.63 (d, J = 4 Hz, 4H, Ph-H),
(
5 5
NMR (125 MHz, C D
1
2
3
8
1
0.62 (s, 2H, meso-H). 13C NMR (125 MHz, C
5 5
D N) d: 16.91, 20.62,
2
4
1
8.48, 31.44, 31.62, 32.98, 33.83, 35.75, 39.35, 40.11, 43.39,
9.15, 52.78, 54.13, 69.44, 69.51, 70.77, 85.59, 87.66, 88.83,
04.25, 123.33, 123.39, 135.31, 136.01, 145.70, 166.80, 204.83.
1.77, 22.62, 24.03, 26.74, 29.67, 29.84, 31.20, 32.06, 33.96,
7.55, 38.33, 41.62, 47.37, 51.01, 52.36, 67.65, 67.73, 68.98,
3.80, 85.80, 86.95, 105.79, 119.12, 121.54, 131.00, 132.20,
MS MALDI-TOF m/z (rel. int.%): 1772 [M+H] (100). HR ESIMS m/z:
+
33.58, 134.47, 143.95, 145.39, 147.00, 165.08, 203.08. MS MAL-
1
771.7524 [M+H] (calcd for C98
102 2 10 4
H B F N O14+H, 1771.7497).
+
DI-TOF m/z (rel. int.%): 1440 [M+H] (100), 996 (60). HR ESIMS
m/z: 1439.7839 [M+H] (calcd for C86H B N O14+H, 1439.7813).
104 2 4
+
2.2.13. Conjugate of 5,15-bis[4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)phenyl]-10,20-bispentafluorophenylporphyrin with
24-epibrassinolide (17)
2.2.11. Conjugate of 5,15-bis(4-dioxylborylphenyl)porphyrin with 24-
epibrassinolide (15)
Product 15 (20 mg, 85%) was obtained as a purple solid from
porphyrin 10 (8 mg, 0.015 mmol) and EBl (prepared according to
Conjugate 17 (19 mg, 80%) was prepared as purple solid from
porphyrin 11 (12 mg, 0.014 mmol) and EBl (prepared according
to [36], 15 mg, 0.031 mmol). m.p. (MeOH): >350 °C. H NMR
1
1
[
(
(
(
36], 15 mg, 0.032 mmol). m.p. (MeOH): >350 °C.
H
NMR
(500 MHz, C
5
D
5
N) d: À2.68 (s, 2H, NH), 0.73 (s, 6H, C18–H), 0.90
500 MHz, C
5
D
5
N) d: À2.68 (s, 2H, NH), 0.75 (s, 6H, C18–H), 0.94
(d, J = 7 Hz, 6H, C21–H), 1.08 (m, 18H, C19–H, C26/C27–H), 1.19
(d, J = 6 Hz, 6H, C24–H), 3.67 (dd, J = 12, 4 Hz, 2H, C5–H), 3.99–
4.25 (m, 6H, C2–H, C7–H), 4.33 (dd, J = 9, 5 Hz, 2H, C23–H), 4.45
(br.s, 2H, C3–H), 4.68 (d, J = 4.5 Hz, 2H, C22–H), 8.52 (d, J = 8 Hz,
4H, Ph-H), 8.61 (d, J = 8 Hz, 4H, Ph-H), 9.27 (d, J = 5 Hz, 4H, pyr-
role-H), 9.46 (d, J = 5 Hz, 4H, pyrrole-H). MS MALDI-TOF m/z (rel.
d, J = 7 Hz, 6H, C21–H), 1.12 (m, 18H, C19–H, C26/C27–H), 1.26
d, J = 6 Hz, 6H, C24–H), 3.68 (dd, J = 12, 4 Hz, 2H, C5–H), 4.04–
4
(
4
.23 (m, 6H, C2–H, C7–H), 4.38 (dd, J = 9, 5 Hz, 2H, C23–H), 4.46
br.s, 2H, C3–H), 4.71 (d, J = 5 Hz, 2H, C22–H), 8.46 (d, J = 8 Hz,
H, Ph-H), 8.64 (d, J = 8 Hz, 4H, Ph-H), 9.22 (d, J = 5 Hz, 4H,
Scheme 1. Reagents and conditions: (a) i: BF
3
ÁEt
2 2 2 2
O, CH Cl , 45 min, r.t., ii: DDQ, 1 h, r.t.; (b) HClconc, THF–H O (4:1).